Life Sciences Venture Investments Still Have a Pulse

Several leading hedge funds specializing in life sciences and biopharma have been more active in the private markets this quarter. But overall volume is still way down from the highs.

Stephen Taub March 24, 2022

Carsten Snejbjerg/Bloomberg

Life sciences and biopharma hedge fund firms ramped up their venture capital activity in the first quarter, after most of them sharply pulled back in the three months ending in December.Even so, the number of private investments is still way behind the pace set during

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

develop build:2025-12-18 Login